Coen Steven P. 4

What Happened
Steven Coen, Chief Financial Officer of Ginkgo Bioworks (DNA), had performance-based restricted stock units (PSUs) convert into 73,921 shares of Class A common stock on April 10, 2026 (two PSU awards: 28,368 and 45,553 shares). On April 13, 2026 he sold 33,171 of those shares in an open-market transaction at $6.41 per share for total proceeds of $212,759. The sale was a sell-to-cover to satisfy tax withholding tied to the PSU vesting.

Key Details

• Transaction dates: PSUs converted to shares on 2026-04-10; open-market sale on 2026-04-13.
• Sale price and value: 33,171 shares sold at $6.41 each, proceeds $212,759.
• Shares involved: 73,921 total shares distributed on vesting (28,368 and 45,553 from two PSU grants); 33,171 sold to cover taxes.
• Shares remaining (after sell-to-cover): approximately 40,750 shares retained (73,921 vested − 33,171 sold), per the filing.
• Footnotes: F1–F4 explain PSUs convert 1:1 into Class A shares and detail the original PSU grants and performance payout rates (62% and 67% of targets). F2 confirms the sale was to satisfy tax withholding and not a discretionary trade.
• Timeliness: Form 4 was filed April 14, 2026 for a report period of April 10, 2026 — the filing appears timely under Form 4 rules.

Context

• PSUs are performance-based awards that convert to shares when performance periods end and targets are certified; here the Compensation Committee certified partial payouts for two 2025 grants.
• The sequence (PSU conversion followed by a sell-to-cover) is common when companies or executives sell a portion of vested shares to meet tax obligations; per the filing, this sale was for tax withholding and not an independent, discretionary sale decision.
• This filing does not indicate other discretionary buying or selling by the CFO beyond the sell-to-cover.